Are Smart Investors Making the Right Decision? Impel Pharmaceuticals Inc. (IMPL)

Impel Pharmaceuticals Inc. (NASDAQ: IMPL) stock jumped 0.31% on Monday to $0.64 against a previous-day closing price of $0.64. With 0.26 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.53 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7001 whereas the lowest price it dropped to was $0.5800. The 52-week range on IMPL shows that it touched its highest point at $7.39 and its lowest point at $0.28 during that stretch. It currently has a 1-year price target of $40.00. Beta for the stock currently stands at -0.03.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMPL was up-trending over the past week, with a rise of 56.30%, but this was up by 0.94% over a month. Three-month performance dropped to -52.16% while six-month performance fell -38.95%. The stock lost -91.27% in the past year, while it has lost -82.91% so far this year. A look at the trailing 12-month EPS for IMPL yields -3.86 with Next year EPS estimates of -0.87. For the next quarter, that number is -0.36. This implies an EPS growth rate of 13.60% for this year and 44.90% for next year.

Float and Shares Shorts:

At present, 23.75 million IMPL shares are outstanding with a float of 16.60 million shares on hand for trading. On Aug 30, 2023, short shares totaled 0.51 million, which was 2.13% higher than short shares on Jul 30, 2023. In addition to Mr. Adrian Adams as the firm’s Chairman, CEO & Pres, Mr. Leonard S. Paolillo serves as its Chief Commercial Officer.

Institutional Ownership:

Through their ownership of 74.61% of IMPL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 4.42% of IMPL, in contrast to 3.15% held by mutual funds. Shares owned by individuals account for 1.19%. As the largest shareholder in IMPL with 2.13% of the stake, The Vanguard Group, Inc. holds 505,231 shares worth 505,231. A second-largest stockholder of IMPL, Avenue Capital Management II LP, holds 408,329 shares, controlling over 1.72% of the firm’s shares. DCF Capital LLC is the third largest shareholder in IMPL, holding 303,605 shares or 1.28% stake. With a 1.67% stake in IMPL, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 396,809 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.41% of IMPL stock, is the second-largest Mutual Fund holder. It holds 96,137 shares valued at 44223.0. Bridgeway Ultra Small Company Mar holds 0.25% of the stake in IMPL, owning 60,000 shares worth 27600.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, IMPL reported revenue of $2.80M and operating income of -$20.98M. The EBITDA in the recently reported quarter was -$20.69M and diluted EPS was -$1.09.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IMPL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With IMPL analysts setting a high price target of $40.00 and a low target of $40.00, the average target price over the next 12 months is $40.00. Based on these targets, IMPL could surge 6150.0% to reach the target high and rise by 6150.0% to reach the target low. Reaching the average price target will result in a growth of 6150.0% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded IMPL stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 10,571 while 3,627 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *